COVID-19 Antivirals: Treatment Options, Eligibility & Side Effects
Antivirals are medications that directly inhibit viral replication—unlike antibiotics, which target bacteria. For COVID-19, early antiviral treatment (within 5–7 days of symptom onset) reduces viral load, accelerates recovery, and—critically—lowers risk of hospitalization and death in high-risk individuals.
Authorized COVID-19 Antivirals (U.S., 2024)
- Nirmatrelvir/ritonavir (Paxlovid®): Oral, 300/100 mg (two 150 mg nirmatrelvir + one 100 mg ritonavir) twice daily × 5 days. Start within 5 days of symptom onset. For adults and children ≥12 years (≥40 kg) at high risk for severe COVID-19. Ritonavir boosts nirmatrelvir via CYP3A4 inhibition—major drug interaction potential (statins, anticoagulants, immunosuppressants, etc.). eGFR adjustment needed (<30: not recommended; 30–60: dose reduce).
- Molnupiravir (Lagevrio®): Oral, 800 mg four times daily × 5 days. Start within 5 days. For adults ≥18 at high risk. Mutagenic mechanism (lethal mutagenesis)—not for pregnancy (animal fetal harm); contraception required. No major drug interactions. Less effective than Paxlovid in clinical trials.
- Remdesivir (Veklury®): IV infusion, 200 mg day 1 then 100 mg daily × 3 days (outpatient) or 5–10 days (hospitalized). Start within 7 days (outpatient). For hospitalized adults/children ≥28 days/≥3 kg with severe COVID-19, or high-risk outpatients. Renal monitoring (eGFR ≥30 for outpatient).
- Ensitrelvir (Xocova®): Oral, once daily × 5 days. Approved in Japan; under FDA review. 3CL protease inhibitor. Data for mild-moderate COVID-19.
Eligibility: "High Risk" Criteria
≥65 years, obesity (BMI ≥25), pregnancy, current/former smoker, chronic conditions: heart/lung/kidney/liver disease, diabetes, immunosuppression, cancer, sickle cell, neurodevelopmental disorders, medical technological dependence. Most adults qualify. Check CDC/NIH guidelines for current list.
Access & Prescribing
- Prescription only. Test-to-Treat sites (pharmacies, clinics) offer same-day testing + prescribing.
- Telehealth visits widely available for prescription.
- Patient assistance programs for uninsured/underinsured.
Side Effects
- Common (mild): Nausea, diarrhea, dysgeusia (Paxlovid "metal mouth"), headache, myalgia, fatigue.
- Paxlovid rebound: Symptom/viral load recurrence ~3–7 days post-treatment (10–20%). Usually mild; not treatment failure. Re-isolate; no re-treatment needed.
- Rare serious: Hepatotoxicity, hypersensitivity, anaphylaxis. Molnupiravir: theoretical mutagenicity concern (no human signal).
Antivirals are powerful tools that change COVID-19 from a high-stakes gamble to a manageable illness for high-risk people. Know your eligibility. Act fast—timing is everything.
Viral Infections - Related Articles
- Poliomyelitis (Polio): Viral Infection of Spinal Cord Gray Matter
- Persistent Viral Infections: Latency, Slow Replication, and Immune Evasion
- Monkey B Virus (Herpes B): Transmission, Symptoms, and Prevention
- How Viruses Make Us Sick: Direct Damage and Immune Overreaction
- Thread Viruses: Mechanism, Threats, and Defense Strategies
- Viral Infections and Blood Sugar: Understanding the Link
- File Types That Can Carry Malware: Risks & Protection Guide
